Novel TGF-β inhibitors ready for prime time in onco-immunology

Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees.

Detalles Bibliográficos
Autores principales: de Gramont, Armand, Faivre, Sandrine, Raymond, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Point of View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283641/
https://www.ncbi.nlm.nih.gov/pubmed/28197376
http://dx.doi.org/10.1080/2162402X.2016.1257453
Descripción
Sumario:Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees.

Ejemplares similares